MedTrace Logo

Effects of Wild Blueberry Ingestion on Motor Performance of People With Parkinson's Disease

NCT07720869 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-07-24

No results posted yet for this study

Summary

The purpose of this study involved investigating the effects of daily ingested wild blueberry drink (22.5 g wild blueberry powder added to pineapple juice) for 8 weeks on movement of people diagnosed with Parkinson's disease. Specifically, the investigators questioned:

* Do the movements of people with Parkinson's disease improve after ingesting the blueberry drink once a day for 8 weeks?
* Do the movements of people with Parkinson's disease after ingesting the blueberry drink show benefits compared to people with Parkinson's ingesting a placebo drink?

Participants will:

* Drink blueberry drink or placebo once a day for 8 weeks
* Visit the neurologist before and after the intervention period
* Complete assessments before and after the intervention period
* Visit the lab weekly for checkups and to obtain more powder and juice
* Keep a diary of time of ingestion and adverse effects. The investigators hypothesized that supplementation with wild blueberry powder will result in favorable improvements in movements in people with Parkinson's disease that exceed placebo supplementation.

Conditions

Interventions

DIETARY_SUPPLEMENT

Wild blueberry powder

Experimental (BB): The experimental powder consists freeze-dried wild blueberry powder included quick frozen and dehydrated wild blueberries to reduce the moisture content to approximately 2-4%. Added to 6oz of pineapple juice.

OTHER

Placebo

Placebo Comparator (Placebo): Placebo drink consists of matched nutritional properties minus the polyphenols for BB powder. Added to 6oz of pineapple juice.

Sponsors & Collaborators

  • Pennington Biomedical Research Center

    collaborator OTHER

  • Baton Rouge Neuromedical Center, The Spine Hospital of Louisiana

    collaborator UNKNOWN

  • Louisiana State University, Baton Rouge

    lead OTHER

Principal Investigators

  • Jan M Hondzinski, PhD · Louisiana State University Health Sciences Center in New Orleans

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2025-04-18
Completion
2025-04-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07720869 on ClinicalTrials.gov